IBS-C
New agreement gives AstraZeneca full responsibility for Linzess in China
September 18, 2019Research and Development AstraZeneca, IBS-C, Linzess
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China for Linzess (linaclotide), a first-in-class new treatment for patients …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
